Natural product-derived therapy for glucose homeostasis and TIIDM: Mangiferin (MA), found in Mangoes and Iris Unguicularis among others, increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of their target gene, 10/April/2017, 11.35 am

Natural product-derived antiviral therapy for HIV virus: Genistein, an isoflavone isolated from Soy products, increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production via up regulation of its target gene, 10/April/2017, 12.01 am
April 9, 2017
Amino-acid based therapy for tuberculosis:L-Leucine, a branched-chain amino acid (BCAA), deacetylates RelA/p65, inhibits inflammatory gene expression downstream of RelA/p65, inhibits TB pathogenesis, increases the efficacy of anti-TB drug, and promotes M. tuberculosis clearance via up regulation of its target gene, 10/April/2017, 10.45 pm
April 10, 2017
Show all

Introduction: What they say 

A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel shows that “PAX6 maintains ß cell identity by repressing genes of alternative islet cell types.” This research paper was published in the 12 December 2016 issue of the journal “Journal of Clinical investigations” [One of the best research journals in Clinical Medicine with an I.F of 12.575] by                 Prof. Yuval Dor and Avital Swisa and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Natural product-derived therapy for glucose homeostasis and TIIDM: Mangiferin (MA), found in Mangoes and Iris Unguicularis among others, increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of their target gene


From Significance of the study to Public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


What is known?

Prof. Yuval Dor’s research team has recently shown that deletion of Pax6 in mice results in: (1) Hyperglycemia; (2) Ketosis (higher levels of 3-hydroxybutyrate and acetoacetate); (3) down regulation of Mafa, Insulin, Nkx6.1, Pdx1, Isl1, Foxa2, Slc2a2 (GLUT2), G6pc2, and Slc30a8; (4) up regulation of glucagon, somatostatin, ghrelin, Neurog, gastrin, and pancreatic polypeptide; (5) loss of ß cell differentiation and function; and (6) expansion of α-cells.

Further, they have shown that: (1) Pax6 increases the expression of insulin; (2) Pax6 decreases the expression of islet cell genes, such as ghrelin, glucagon, somatostatin, FOXA2, and Neurog3; (3) Pax6 is down regulated in ß cell of diabetic mice; and (4) Pax6’s function is preserved in pancreatic ß cells of human, suggesting that increasing the expression of Pax6 in diabetic patients may alleviate TIIDM.


From Research findings to Therapeutic opportunity:

Mangiferin, by increasing the expression of its target gene, it may increase the expression of Pax6 (fig.1).

Mangiferin induces Pax6 expession and promotes insulin sensitivity

Figure 1. Mechanistic insights into how Mangiferin functions as an anti-hyperglycemic agent.  Mangiferin, by up regulating Pax6 and insulin expression and by downregulating the levels of glucagon, ghrelin and Somatostatin, it may prevent the progression of TIIDM.

[easy_payment currency=”USD”]

Thereby, it may: (1) increase insulin sensitivity; (2) inhibit the expression of islet cell genes, including glucagon, ghrelin and Somatostatin; (3) increase the expression of Mafa, Insulin, Nkx6.1, Pdx1, Isl1, Foxa2; (4) decrease metabolic stress; and (5) promote glucose homeostasis (Fig.1). Thus, pharmacological formulations encompassing “Mangiferin (MA) or its analogues either alone in combination with other natural products/drugs” may be used to treat TIIDM.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-a
nd-conditions/

Undisclosed mechanistic information: How Mangiferin increases the expression of Pax6 to promote insulin sensitivity

Amount: $200#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Natural product-derived therapy for glucose homeostasis and TIIDM: Mangiferin (MA), found in Mangoes and Iris Unguicularis among others, increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of their target gene, 10/April/2017, 11.35 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.